Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Brainstorm Cell Therapeutics ($BCLI) announced that it has been awarded $16 million by the California Institute for Regenerative Medicine. The funds will be used for support the company’s pivotal Phase 3 clinical trial assessing NurOwn for the treatment of amyotrophic lateral sclerosis. The primary endpoint of the study will be the ALSFR-S score responder analysis. The study is expected to enroll nearly 200 patients across six U.S. sites.
The company stock reacted positively to the news and gained over 9 percent in its previous trading session, taking its Year to Date gain to 94 percent. The company stock is up 105 percent in the past 12 months.

Nektar Therapeutics ($NKTR) announced its new collaboration with Eli Lilly. The collaboration pertains to the development of NKTR-358, designed to treat autoimmune and other chronic inflammations. The deal is expected to be worth $150 million and entails up to $250 million in additional milestone payments. Nektar looks to complete its Phase 1 clinical development whereas Eli Lilly will bear 75 percent of the Phase 2 development costs. Eli Lilly will also be responsible for global commercialization expenses. Nektar retains the option to collaborate in late stage developments on an indication by indication basis.
The stock reacted positively to the news and jumped over 4 percent in the pre-market session. It has gained 81 percent this year so far while its 12 months gain stands at 46 percent.


Radius Health ($RDUS) reported that the Committee for Medicinal Products for Human Use's (CHMP) scientific group has issued a second Day-180 List of Outstanding Issues regarding its Marketing Authorization Application. The company is seeking approval for its Eladynos (abaloparatide-SC) for the treatment of postmenopausal women with osteoporosis at high risk of fracture.

Momenta Pharmaceuticals ($MNTA) received a mixed decision with regard to its suit against Amphastar Pharmaceuticals over alleged infringement of a U.S. patent covering LOVENOX (enoxaparin sodium injection). The jury found that the patent was infringed, but unenforceable and invalid.

Bayer ($BAYRY) announced that its anetumab ravtansine failed to show statistically significant increase in progression-free survival (PFS) in a Phase 2 clinical trial in patients with previously treated recurrent malignant pleural mesothelioma.

GlaxoSmithKline ($GSK) announced receiving the FDA approval for its new subcutaneous formulation of Benlysta (belimumab) for the treatment of adults with active, autoantibody-positive systemic lupus erythematosus (SLE) who are also receiving standard therapy. The treatment offers the first self-injection option for SLE patients.


HCA Healthcare ($HCA) inks a deal with Community Health Systems for acquiring Highlands Regional Medical Center in Florida. The companies did not disclose the financial terms of the deal. Highlands Regional is a 126 bed facility.

GlaxoSmithKline ($GSK) announced filing a Marketing Authorization Application with the European Medicines Agency seeking approval for the extended use of asthma med Relvar Ellipta in patients already adequately controlled on an ICS/LABA combination.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Jefferies Group LLC Initiates Aileron Therap (ALRN)
Buy $20.00 Low

Canaccord Genuity Initiates Aileron Therap (ALRN)
Buy $19.00 Low

Bank of America Corporation Initiates Aileron Therap (ALRN)
Buy $19.00 Low

Craig Hallum Initiates Apollo Endosurgery (APEN)
Buy $11.00 Low

First Analysis Downgrades athenahealth (ATHN)
Equal Weight -> Underweight $99.00 -> $125.00 Low

Gainers (% price change)Last TradeChangeMkt CapSarepta Therapeutics IncSRPT43.41+2.48 (6.06%)2.87BCytokinetics, Inc.CYTK14.50+0.65 (4.69%)710.95MBioDelivery Sciences IntlBDSI3.25+0.10 (3.17%)188.80MBioScrip IncBIOS2.98+0.09 (3.11%)349.64MCumberlandCPIX7.08+0.20 (2.91%)113.03MLosers (% price change)Peregrine PharmaceuticalsPPHM4.60-0.62 (-11.88%)208.12MAchillion PharmaceuticalsACHN4.11-0.21 (-4.86%)556.78MFluidigm CorporationFLDM3.72-0.18 (-4.62%)109.99MIntuitive Surgical, Inc.ISRG927.47-44.26 (-4.55%)34.34BImmunoGen, Inc.IMGN5.66-0.24 (-4.07%)500.62MMost Actives (dollar volume)Intuitive Surgical, Inc.ISRG927.47-44.26 (-4.55%)34.34BUnitedHealth Group IncUNH191.78+0.17 (0.09%)187.07BJohnson & JohnsonJNJ135.31-1.26 (-0.92%)368.17BGilead Sciences, Inc.GILD73.76+0.34 (0.46%)97.31BVertex PharmaceuticalsVRTX163.17+3.84 (2.41%)40.55B